Virtually all cases of PTFL, even if treated with minimal interventions such as surgical removal or a watch-and-wait approach, have had a relatively benign and sometimes remitting and relapsing course. Thus, past recommendations that these patients need to be evaluated by bone marrow biopsy, lumbar puncture, or other invasive and/or expensive procedures requires revaluation. The evaluation of therapeutic regimens used to treat PTFL is complicated by their purely retrospective nature and inclusion of cases which in retrospect were likely cases of large B-cell lymphoma with IRF4 rearrangement. In any event, many of these cases were treated with chemotherapeutic regimens, principally, CHOP (i.e. cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) or R-CHOP (i.e. CHOP plus rituximab) while others, which likely excluded large B-cell lymphoma with IRF4 rearrangement, were treated with surgical removal, localized radiation therapy, and/or watch-and-wait strategies. All of these treatments have yielded in<unk>  patients overall survival rates of 100% and relapse rates of 0 to 6% as observed over variable observation periods of up to 5 years. Among this group, 36<unk>  patients were treated with surgical resection alone followed by observation with all patients surviving and only one having a relapse. Most adults with PTFL have been treated more vigorously with regimens consisting of immunochemotherapy (e.g. R-CHOP) and/or radiation therapy. This more vigorous approach has been used because the distinction between PTFL and aggressive<unk>  lymphoma is not as clear in adults as it is in younger patients. Thus, current recommendations for the treatment of<unk>  PTFL patients is watch-and-wait following radiation therapy or complete surgical resection; in cases where surgical resection is incomplete, immunechemotherapy is added to the regimen. The recommended treatment of adults with PTFL is less clear. Currently used regimens rely on immunochemotherapy but might change if the issue of discriminating PTFL from<unk>  lymphoma can be resolved.
Pediatric-type follicular lymphoma
Nodal marginal zone B cell lymphoma
Duodenal-type follicular lymphoma
Marginal zone B-cell lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma
Follicular lymphoma
Indolent lymphoma
AIDS-related lymphoma